Mononit 10 (Isosorbide Mononitrate)

Isosorbide mononitrate is used within the anti‑anginal drug class to manage coronary artery disease‑related chest pain.

• Angina pectoris (prophylaxis): reduces the frequency of angina attacks.
• Chronic stable angina (treatment): improves exercise capacity and symptom control.
• Ischemic heart disease (symptom relief): decreases myocardial oxygen demand and alleviates chest discomfort.

• Isosorbide mononitrate is metabolized to release nitric oxide, which activates guanylate cyclase in vascular smooth muscle. The resulting increase in cyclic GMP causes relaxation of arterial and venous vessels, producing vasodilation that lowers preload and afterload, thereby reducing myocardial oxygen consumption and relieving angina.

Isosorbide mononitrate may cause a range of adverse reactions.

Common Side Effects

• Headache: often transient and related to vasodilation.
• Dizziness or light‑headedness: due to lowered blood pressure.
• Flushing: warm sensation, especially after the first dose.
• Nausea: mild gastrointestinal upset.
• Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Syncope: fainting episodes associated with low pressure.
• Life‑threatening allergic reaction: rash, swelling, or difficulty breathing.
• Arrhythmias: abnormal heart rhythms in susceptible patients.
• Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, consider the following safety measures.

• Dose titration: start with a low dose and increase gradually as tolerated.
• Renal impairment: evaluate kidney function and adjust if severe.
• Hepatic impairment: use with caution in patients with liver disease.
• Concomitant nitrates: avoid simultaneous use to prevent additive hypotension.
• Pregnancy and lactation: assess risk‑benefit and consult a specialist.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Isosorbide mononitrate can interact with several medication groups.

Major Interactions (Avoid)

• Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of profound hypotension.
• Other organic nitrates (e.g., nitroglycerin): additive vasodilatory effect.
• Antihypertensive agents (e.g., ACE inhibitors, ARBs): may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive response.
• Beta‑blockers: can mask tachycardia signs of hypotension.
• Alcohol: may increase dizziness and low‑blood‑pressure effects.